A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 8, 2005, Pages 451-454

  Zarghi, Afshin ^a   Shafaati, Alireza ^a   Foroutan, Seyyed Mohsen ^a   Khoddam, Arash ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Noor Research and Educational Institute   (Iran)

Author keywords

Atorvastatin, determination in plasma, HPLC method; CAS 134523 00 5; Hypolipidemic agent

Indexed keywords

ACETONITRILE; ANTILIPEMIC AGENT; ATORVASTATIN; DILTIAZEM;

ACIDITY; ADULT; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRECIPITATION; STANDARD; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 23944514293     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296887     Document Type: Article

References (15)

1. Malhotra, H. S., Goa, K. L., Atorvastatin: an updated review of its pharmacological properties and use in dyslipiaemias. Drugs. 61, 1835 (2003)
2. Klotz, U., Pharmacological comparison of the statins. Arzneim.-Forsch./Drug Res. 53, 605 (2003)
3. Williams, D., Feely, J., Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41, 343 (2002)
4. Lennernas, H., Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet, 42, 2253 (1998)
5. Shum, Y. Y., Huang, N., Walter, G. et al., Development, validation, and interlabratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther. Drug Monit. 20, 41 (1998)
6. Altuntas, T. G., Erk, N., Liquid chromatographic determination of atorvastatin in bulk drug, tablets, and human plasma. J. Liq. Chromatogr. Related Tech. 27, 83 (2004)
7. Erturk, S., Aktas, E. S., Ersoy, L. et al., An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal. 33, 1017 (2003)
8. Al-Rawithi, S., Hussein, R. F., Navarro, A. S. et al., Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. Ther. Drug Monit. 25, 88 (2003)
9. Bullen, W. W., Miller, R. A., Hayes, R. N., Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, orthohydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J. Am. Soc. Mass Spectrom. 10, 55 (1999)
10. Jemal, M., Ouyang, Z., Chen, B. C. et al., Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 13, 1003 (1999)
11. Koytchev, R., Ozalp, Y., Erenmemisoglu, A. et al., Bioequivalence study of atorvastatin tablets. Arzneim.-Forsch./ Drug Res. 54, 573 (2004)
12. Miao, X. S., Metcalfe, C. D., Determination of pharmaceuticals in aqueous samples using positive and negative voltage switching microbore liquid chromatography/electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 38, 27 (2003)
13. Van Pelt, C. K., Corso, T. N., Schultz, G. A. et al., A four-column parallel chromatography system for isocratic or gradient LC/MS analyses. Anal. Chem. 73, 582 (2001)
14. Erturk, S., Onal, A., Muge Cetin, S., Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793, 193 (2003)
15. Posvar, E. L., Radulovic, L. L., Cilia, D. D. et al., Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in heathy subjects. J. Clin. Pharmacol. 36, 728 (1996)